PD-1 upregulation enhances the immunosuppression of group 2 innate lymphoid cells by boosting IL-4 and IL-13 secretion in human non-small cell lung cancer

Chaojun Liu

Zhengzhou University First Affiliated Hospital

Chunyi Shen

Zhengzhou University First Affiliated Hospital

Zhen Zhang

Zhengzhou University First Affiliated Hospital

Yu Ping

Zhengzhou University First Affiliated Hospital

Jingwen Shao

Zhengzhou University First Affiliated Hospital

Yonggui Tian

Zhengzhou University First Affiliated Hospital

Weina Yu

Zhengzhou University First Affiliated Hospital

Guohui Qin

Zhengzhou University First Affiliated Hospital

Shasha Liu

Zhengzhou University First Affiliated Hospital

Liping Wang

Zhengzhou University First Affiliated Hospital

Yi Zhang (✉ yizhang@zzu.edu.cn)

The First Affiliated Hospital of Zhengzhou University <https://orcid.org/0000-0001-9861-4681>

Research

Keywords: innate immune response, non small cell lung cancer, programmed cell death protein 1, group 2 innate lymphoid cells, type 2 macrophage

Posted Date: September 1st, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-66230/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Title: PD-1 upregulation enhances the immunosuppression of group 2 innate lymphoid cells by boosting IL-4 and IL-13 secretion in human non-small cell lung cancer

Authors: Chaojun Liu^{1,#}, Chunyi Shen^{1,#}, Zhen Zhang^{1,2}, Yu Ping¹, Jingwen Shao¹, Yonggui Tian¹, Weina Yu¹, Guohui Qin^{1,2}, Shasha Liu¹, Liping Wang³, and Yi Zhang^{1,2,4,*}

Affiliations:

¹Biotherapy Center and Cancer Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China

²State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, 450052, China.

³Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China

⁴Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, 450052, China

[#] C. Liu and C. Shen contributed equally to this article.

***Corresponding author:** Prof. Yi Zhang, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe road, Zhengzhou, Henan, 450052, China. Tel./ Fax: +86-371-6691-5320. E-mail address: yizhang@zzu.edu.cn

Running title: PD-1^{high} ILC2s suppress human NSCLC immunity via IL-4/IL-13

Keywords: innate immune response, non-small cell lung cancer, programmed cell death protein 1, group 2 innate lymphoid cells, type 2 macrophage

Abstract

Background: There is increasing evidence that group 2 innate lymphoid cells (ILC2s) play an essential role in allergy and parasitic infection. However, the role of ILC2s in human lung cancer remains unclear.

Methods: ILC2s from peripheral blood mononuclear cells (PBMCs) obtained from healthy donors (HDs) and non-small cell lung cancer (NSCLC) patients, and NSCLC tumor tissues were analyzed via multicolor flow cytometry. ILC2s or CD14⁺ cells were sorted by fluorescence-activated cell sorting. qPCR and flow cytometry were performed to assess the gene and protein expression of the indicated molecules. M1-like and M2-like macrophages were induced from CD14⁺ monocytes in vitro.

Results: ILC2s were significantly more enriched in PBMCs and tumor tissues from NSCLC patients than in HDs. After screening for the main immune checkpoint molecules, we found that PD-1 was upregulated in ILC2s in NSCLC patients. Functionally, PD-1^{high} ILC2s from tumor tissues expressed higher levels of IL-4 and IL-13 regarding both mRNA and protein levels than PD-1^{low} ILC2s. Furthermore, PD-1^{high} ILC2s robustly boosted M2-like macrophage polarization in vitro, by secreting IL-4 and IL-13, while neutralization of IL-4 and IL-13 by antibodies abrogated M2-like macrophage polarization.

Conclusion: ILC2s are enriched in NSCLC patients and upregulate PD-1 expression. Upregulation of PD-1 facilitates the immunosuppressive function of ILC2s. PD-1^{high} ILC2s enhance M2-like macrophage polarization by secreting IL-4 and IL-13. PD-1 acts as a positive regulator of the immunosuppressive function of ILC2s in human

45 NSCLC.

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Introduction

Generally, the family of innate lymphoid cells (ILCs) comprises two cardinal lineages: cytotoxic or killer ILCs (cNK cells) and helper-like ILCs (ILC1s, ILC2s, and ILC3s) (1-3). The transcriptional programs and effector functions of various ILC populations resemble those of CD4⁺ helper T cell subsets (4). For example, specific transcriptional factor GATA3 controls the fate and maintenance of Th2 cells and ILC2s, both of which produce mainly type 2 cytokines, such as interleukin (IL)-4 and IL-13 (5-7).

Inflammatory processes play major roles in diverse cancers, including lung cancer, and facilitate tumor initiation, progression, and metastasis (8,9). An increasing number of studies have demonstrated that ILC2s played an essential role in the inflammatory processes that underlie allergy and parasitic infection (10-12). Some studies have investigated the role of ILC2s in tumor settings. In a mouse model of melanoma, ILC2s were found to inhibit NK cell activation and cytotoxicity, thereby further aggravating tumor progression (13). In addition, ILC2s enhanced the accumulation of myeloid-derived suppressor cells (MDSCs) by upregulating IL-13, which was involved in the recurrence of bladder cancer (14). In a 4T1 breast cancer mouse model, Ivan et al. reported that IL-5 and IL-13-expressing ILCs hastened tumor progression and metastasis; unfortunately, the authors did not confirm whether the ILCs expressing IL-5 and IL-13 were ILC2s (15). Most recently, Trabanelli et al. summarized the evidence from research about ILC2s in tumors and found that the majority of studies declared that ILC2s functioned as a pro-tumor factor by activating

and/or recruiting other stromal cells (16). Lung cancer, the commonest of which is non-small cell lung cancer (NSCLC), has the highest incidence and mortality rate among various tumors worldwide (17). However, little is known about the role of ILC2s in human lung cancer.

In the present study, we found that ILC2s were enriched in peripheral blood and tumor tissues of patients with NSCLC, and showed a more powerful immunosuppressive function than ILC2s obtained from healthy donors (HDs). PD-1 was upregulated in ILC2s obtained from NSCLC patients and boosted the expression of IL-4 and IL-13. Furthermore, the upregulation of PD-1 in ILC2s could increase M2-like macrophage polarization via IL-4 and IL-13. Our findings suggest that PD-1 plays an important role in the immunosuppressive function of ILC2s in human NSCLC.

Materials and methods

Patients and healthy donors

Peripheral blood samples and fresh tumor tissues were obtained from 70 patients with NSCLC at the First Affiliated Hospital of Zhengzhou University. Written informed consent was obtained from each subject enrolled in this study. The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. Details of the clinicopathologic features of these patients are summarized in Supplementary Table S1. The peripheral blood samples from 20 HDs were used as control.

Acquisition of peripheral blood mononuclear cells and tumor tissue single cell suspension

Peripheral blood samples were subjected to Ficoll–Paque density gradient centrifugation at 2,500 rpm for 25 mins. Peripheral blood mononuclear cells (PBMCs) were extracted and washed twice with sterile phosphate buffered saline (PBS) (cat# P1020; Solarbio, China). Fresh tumor tissues were dissociated into single cell suspensions utilizing the human tumor dissociation kit (cat# 130-095-929; Miltenyi, Germany) following the manufacturer's instructions. Tumor tissue single cell suspensions were filtered using a 70 µm cell strainer and then washed twice with PBS for subsequent flow cytometry testing or cell sorting.

Flow cytometry analysis

Human ILC2s were identified utilizing the CD45⁺Lin⁻CD127⁺CRTH2⁺ gate strategy described in previous studies (18-20). Cell surface molecules were stained by incubating PBMCs and the tumor tissue single cell suspension with fluorochrome-conjugated primary antibodies away from light for 20 mins at 4°C. Intracellular staining of IL-4, IL-13, p-AKT, p-S6, and p-STAT5 was executed as described in a previous study (21). The cells were tested and analyzed utilizing the flow cytometry system (Canto II; BD Biosciences, USA).

The following anti-human monoclonal antibodies were used for flow cytometry (all purchased from BioLegend [San Diego, CA, USA] except when indicated): anti-CD45 FITC (cat# 368508; clone: 2D1), anti-CD45 PerCP-Cy5.5 (cat# 368506; clone: 2D1), anti-CD127 (IL7R) PerCP-Cy5.5 (cat# 351322; clone: A019D5), anti-CD127 PE (cat# 351316; clone: A019D5), anti-CD279 (PD-1) PE (cat# 329906; clone: EH12.2H7), anti-CD279 PE-Cy7 (cat# 329918; clone: EH12.2H7); anti-CD294 (CRTH2) APC-Cy7 (cat# 350113; BM16), anti-CD117(c-kit) PE (cat# 313204; clone: 104D2), and APC anti-human lineage cocktail (cat# 348803; clone: UCHT1 [CD3], HCD14 [CD14], 3G8 [CD16], HIB19 [CD19], 2H7 [CD20], and HCD56 [CD56]).

The primary antibodies against phosphorylated AKT (p-AKT, Ser473, clone: D9E, cat # 4060T, dilution 1:100), phosphorylated S6 (p-S6, Ser235/236 clone: D57.2.2E, cat # 4858T, dilution 1:25), and phosphorylated STAT5 (p-STAT5, Tyr694, clone D47E7, cat # 4322T, dilution 1:200) were purchased from Cell Signaling Technology (Boston, USA). The secondary antibodies were FITC Donkey anti-rabbit IgG (cat# 406403, clone: Poly4064; BioLegend) and PE Donkey anti-rabbit IgG (cat# 406421, clone:

Poly4064; BioLegend).

Cell isolation, RNA extraction, and reverse transcription

ILC2s (CD45⁺Lin⁻CD127⁺CRTH2⁺), PD-1^{high} ILC2s, and PD-1^{low} ILC2s were sorted from PBMCs or tumor tissue single cell suspensions by fluorescence-activated cell sorting (FACS) (Moflo XDP; Beckman, USA). Total RNA was extracted from 100–1000 sorted ILC2s cells, PD-1^{high} ILC2s, PD-1^{low} ILC2s, or CD14⁺ cells, and cDNA was simultaneously generated using the single cell sequence specific amplification kit (cat# P621-01; Vazyme Biotech Co. Ltd., China) following the manufacturer's instructions.

Quantitative real-time polymerase chain reaction

Quantitative real-time polymerase chain reaction (qRT-PCR) was performed in with the CFX96 Touch Real-Time PCR Detection System (Bio-Rad, USA) using the ChamQ SYBR Color qPCR Master Mix (cat# Q411-02; Vazyme, China) following the manufacturer's instructions. Target genes were amplified under the following conditions: 95°C for 5 min and 40 cycles of 95°C for 30 sec, 60°C for 30 sec. *GAPDH* was used as the internal control and relative gene expression levels were ascertained by the $2^{-\Delta\Delta C_t}$ method followed by logarithmic transformation to the base 2. The primers of the target genes are listed in Supplementary Table S2.

Macrophage polarization in vitro

CD14⁺ monocytes were sorted from PBMCs of HDs via magnetic-activated cell sorting (cat# 130-118-906; Miltenyi Biotec, Germany) according to the manufacturer's instructions. Sorted PD-1^{high} ILC2s and PD-1^{low} ILC2s were cultured in RPMI 1640 complete medium containing 10% fetal bovine serum (cat# S711-001; LONSERA, Australia) and 1% penicillin-streptomycin solution (cat# P1400; Solarbio, China) with 10 IU/ml of recombinant human IL-2 (cat# 200-02; PeproTech, USA) and 20 ng/ml of IL-7 (cat# 200-07; PeproTech, USA) for 48 h, after which the supernatant was harvested. Sorted CD14⁺ monocyte cells obtained from HD PBMCs were cultured to induce macrophages in complete RPMI 1640 culture medium and 100 ng/ml recombinant human M-CSF (rhM-CSF; cat# 300-25; PeproTech, USA) in a 24-well plate with 1×10^6 cells per well for 7 days (22). Then, the cells were treated with 100 ng/ml of LPS and 20 ng/ml recombinant human IFN- γ (rhIFN- γ ; cat# 300-02; PeproTech, USA) (for M1-like macrophages) or 20 ng/ml recombinant human IL-4 (rhIL-4; cat# 200-04; PeproTech, USA) (for M2-like macrophages) or PD-1^{low} ILC2s culture supernatant or PD-1^{high} ILC2s culture supernatant for 18 h.

With respect to the IL-4 and IL-13 blockade assay, CD14⁺ monocyte cells sorted from HD PBMCs were cultured in RPMI 1640 complete medium and 100 ng/ml of rhM-CSF (PeproTech) in a 24-well plate of 1×10^6 cells per well for 7 days. Then, they were divided into four groups and the following were added: the solute, anti-IL-4 antibody (cat# 500838, clone: MP4-25D2; BioLegend), anti-IL-13 antibody (cat# 501910, clone: JES10-5A2; BioLegend), and anti-IL-4 antibody combined with anti-IL-13 antibody. Two hours later, 100 ng/ml of LPS and PD-1^{high} ILC2s culture

supernatant were added and cultured for an additional 18 hours. The cells were harvested for flow cytometry testing, RNA extraction, and qPCR. The final concentrations of IL-4 and IL-13 antibodies in the medium were 1 µg/ml and 500 ng/ml, respectively.

Statistical analysis

The results of flow cytometry were analyzed using FlowJo software version X (BD, USA). Other analyses were performed using Prism software version 7.0 (GraphPad Software Inc, USA). The results are presented as means with their standard errors. Two-group comparison was performed using the two-tailed student's *t*-test. Comparisons among more than two groups were performed via one-way analysis of variance with Tukey's *post hoc* tests. Analysis items with *P* value less than 0.05 were considered statistically significant.

Results

Identification and distribution of ILC2s among HDs and NSCLC patients

Total ILCs and ILC2s were identified as CD45⁺Lin⁻CD127⁺ cells and CD45⁺Lin⁻CD127⁺CRTH2⁺ cells, respectively, in line with previous studies (18-20). The representative gating strategies are shown in Fig. 1A. The proportions of total ILCs among CD45⁺ cells were measured in HDs and NSCLC patients. There was no significant difference in the proportions of ILCs among CD45⁺ cells obtained from HDs and NSCLC patients (Fig. 1B). Next, the proportions of three ILC subsets were assessed, the representative results of which are shown in Fig. 1C. ILC2s constituted a much higher proportion of total ILCs in PBMCs ($P<0.0001$) and tumor tissues ($P<0.0001$) obtained from NSCLC patients than in PBMCs obtained from HDs (Fig. 1D, Supplementary Fig. 1A). NSCLC patients also showed remarkably decreased and increased the levels of ILC1s and ILC3s, respectively (Supplementary Fig. S1B and S1C). ILC2s were selectively enriched in NSCLC patients, which drove us to explore the correlation between ILC2 levels and tumor stages among NSCLC patients. The proportions of ILC2s among total ILCs in patients with stage III–IV disease were significantly higher than those in patients with stage I–II disease (Fig. 1E, Supplementary Fig. S1D). In addition, ILC1s were decreased in patients with stage III–IV disease, and there was no difference in the level of ILC3s between the two groups (Supplementary Fig. S1E and S1F). Together, these findings indicated that although the proportion of total ILCs among CD45⁺ cells showed no difference, ILC2s were enriched in both PBMCs and tumor tissues obtained from NSCLC

patients and ILC1s decreased in NSCLC patients.

Genetic expression of key phenotypic and functional molecules in ILC2s

Since ILC2s increased in NSCLC patients, we investigated gene expression in ILC2s. ILC2s were sorted from HD PBMCs, and PBMCs and tumor tissues of NSCLC patients via FACS. Total RNA extraction and cDNA generation were performed. Gene expression profiles of key phenotypic and functional molecules of ILC2s were tested by qPCR. There were no difference between NSCLC patients and HDs regarding phenotypic gene expressions of *IL7R*, *CRTH2*, and *ST2*. PBMCs obtained from NSCLC patients, but not tumor tissues, showed increased expression of *KIT*(*CD117*) compared with those from HDs (Supplementary Fig. 2A). Next, the genetic expression of major functional molecules of ILC2s (*IL4*, *IL5*, *IL9*, *IL13*, and *AREG*) (19) were tested (Fig. 2A). *IL4* and *IL13* were highly expressed in ILC2s obtained from tumor tissues (*IL4*, $P<0.0001$; *IL13*, $P<0.0001$) and PBMCs (*IL4*, $P<0.0001$; *IL13*, $P<0.0001$) obtained from NSCLC patients than those obtained from HDs (Fig. 2B and 2C). In addition, *IL4* expression in ILC2s obtained from tumor tissues was higher than NSCLC PBMCs (Fig. 2B), while there was no distinction in *IL13* expression between these two groups (Fig. 2C). Intriguingly, the expression of *IL5* and *IL9* was increased in ILC2s from PBMCs from NSCLC patients, but not in ILC2s from tumor tissues, compared with HD-derived PBMCs (Supplementary Fig. 2B). This result indicated that the expression of *IL5* and *IL9* in ILC2s might not be affected by tumor site. In addition, there was no difference in *AREG* expression between

NSCLC patients and HDs (Supplementary Fig. 2B). These results showed that *IL4* and *IL13* were upregulated in ILC2s obtained from both PBMCs and tumor tissues of NSCLC patients. Furthermore, the protein levels of IL-4 and IL-13 were confirmed by multi-color flow cytometry. As expected, IL-4 and IL-13 levels were highly increased in ILC2s from PBMCs (IL-4, $P<0.0001$; IL-13, $P<0.0001$) (Fig. 2D and 2E) and tumor tissues (IL-4, $P<0.0001$; IL-13, $P<0.0001$) (Fig. 2F and 2G) of NSCLC patients than in ILC2s from HD PBMCs. We also found that the protein levels of IL-4 and IL-13 of ILC2s from NSCLC tumor tissues were higher than those from NSCLC PBMCs. This implied that certain factors in the tumor microenvironment might further boost the upregulation of IL-4 and IL-13 in tumor tissues. Taken together, these results demonstrated that both IL-4 and IL-13 were upregulated in ILC2s of NSCLC patients, particularly in ILC2s derived from tumor tissues.

Increased expression of PD-1 on ILC2s in NSCLC patients

A previous study demonstrated that PD-1 expression plays an important role in ILC2 development and function (23). Thus, we explored the gene expression profile of *PDCDI* (encoding PD-1) as well as other cardinal immune checkpoint molecules in ILC2s from NSCLC patients. ILC2s were sorted from HD-derived PBMCs and NSCLC patient-derived PBMCs and tumor tissues via FACS, and then subjected to RNA extraction and qPCR. The representative data in a heatmap are shown in Fig. 3A. *PDCDI* was obviously upregulated in ILC2s obtained from PBMCs ($P<0.0001$) and tumor tissues ($P<0.0001$) of NSCLC patients compared with ILC2s from HDs (Fig.

3B). Moreover, *PDCD1* expression was increased in ILC2s obtained from tumor tissues compared with ILC2s obtained from NSCLC PBMCs (Fig. 3B). There were no differences in the expressions of other immune checkpoint genes (*CTLA4*, *TIM3*, and *TIGIT*), except for *LAG3* whose expression in ILC2s from tumor tissues was lower than that in PBMCs from HDs or NSCLC patients (Supplementary Fig. 3). PD-1 on total ILCs obtained from PBMCs ($P<0.0001$) and tumor tissues ($P<0.0001$) of NSCLC patients were significantly upregulated compared with those on ILCs obtained from HD PBMCs (Fig. 3C). In addition, PD-1 expression on ILCs from tumor tissues was higher than that on ILCs from PBMCs of NSCLC patients (Fig. 3C). Next, we investigated the levels of PD-1 on three subsets of ILCs from PBMCs and tumor tissues of NSCLC patients. The proportions of PD-1 expression in ILC2s were much higher than those in ILC1s or ILC3s in both PBMCs (Fig. 3D and 3E) and tumor tissues (Fig. 3F and 3G) from NSCLC patients. Thus, PD-1 was highly expressed on ILC2s obtained from NSCLC patients both in terms of mRNA level and protein level, indicating that PD-1 may function as a regulatory factor, to some degree, in ILC2s from NSCLC patients.

PD-1^{high} ILC2s upregulated the expression of IL-4 and IL-13 in NSCLC patients

Based on the finding that PD-1 was upregulated on ILC2s in NSCLC patients, we hypothesized that PD-1 might play a role in the regulation of ILC2 function. PD-1^{high} and PD-1^{low} ILC2s from human NSCLC tumor tissues were sorted via FACS. We then assessed the genetic expression of ILC2 phenotype, function, and checkpoint

309 molecules via qPCR. As expected, PD-1^{high} ILC2s showed obviously higher *PDCDI*
310 expression than PD-1^{low} ILC2s (Fig. 4A). The expression of *CRTH2* and *ST2* was
311 upregulated in PD-1^{high} ILC2s compared with PD-1^{low} ILC2s, while no difference was
312 found in the expression of *IL7R* and *KIT(CD117)* (Supplementary Fig. 4A).
313 Furthermore, the immune checkpoint molecules *CTLA4*, *HAVCR2 (TIM3)*, and *LAG3*
314 showed comparable levels of gene expression according to the different PD-1 levels,
315 except for *TIGIT* which was highly expressed in PD-1^{high} ILC2s (Supplementary Fig.
316 4B).

317 Regarding the functional molecules of ILC2s, PD-1^{high} ILC2s in tumor tissues
318 expressed much higher levels of *IL4* and *IL13* than did PD-1^{low} ILC2s in terms of
319 mRNA level (Fig. 4B). However, there were no differences in the expression of other
320 functional molecules (*IL5*, *IL9*, and *AREG*) (Supplementary Fig. 4C). Next, we
321 performed flow cytometry to confirm the protein levels of IL-4 and IL-13 in ILC2s.
322 As expected, levels of IL-4 (Fig. 4C and 4D) and IL-13 (Fig. 4E and 4F) were higher
323 in PD-1^{high} ILC2s than in PD-1^{low} ILC2s. Taken together, the upregulation of PD-1 in
324 ILC2s indicated more powerful function, and particularly induced the upregulation of
325 type 2 cytokines (IL-4 and IL-13).

326 327 **Upregulation of PD-1 enhanced the AKT-S6 signaling pathway in ILC2s** 328 **obtained from NSCLC patients**

329 To investigate the downstream signaling pathway of PD-1 in ILC2s, we assessed the
330 phosphorylation levels of the key molecules within the PD-1 signaling pathway (such

as AKT and S6) as previously reported (24,25) via flow cytometry. As a result, PD-1^{high} ILC2s upregulated phosphorylated AKT (p-AKT) compared with PD-1^{low} ILC2s (Fig. 5A and 5B). Similarly, the proportion of phosphorylated S6 (p-S6) in PD-1^{high} ILC2s was significantly increased compared with that in PD-1^{low} ILC2s (Fig. 5C and 5D). These findings suggested that PD-1 upregulation activated its downstream signaling molecules in ILC2s of NSCLC patients. A previous study showed that phosphorylated STAT5 (p-STAT5) was a key downstream molecule of the PD-1 signaling pathway in ILC2s and inhibited IL-5 and IL-13 expression in the context of infection with *Nippostrongylus brasiliensis* (26). This drove us to explore whether STAT5 plays a role in the regulation of cytokine secretion in ILC2s of NSCLC patients. While, we did not find a significant difference in p-STAT5 levels between PD-1^{high} ILC2s and PD-1^{low} ILC2s (Fig. 5E and 5F), suggesting that p-STAT5 played a marginal role in the functional regulation of PD-1 on ILC2s in human NSCLC tumors. Thus, PD-1 upregulation on ILC2s scarcely effects p-STAT5 signaling and may activate the AKT-S6 signaling pathway in NSCLC patients.

PD1^{high} ILC2s enhance the polarization of M2-like macrophages from monocytes

Previous studies have demonstrated that IL-4 and IL-13, two canonical type 2 cytokines, could mediate M2 macrophage polarization (27,28). Considering the upregulation of IL-4 and IL-13 in PD-1^{high} ILC2s, we assessed the effect of ILC2 culture supernatant on the process of CD14⁺ monocyte polarization to M2-like macrophages in vitro. We found that the culture supernatant of PD-1^{high} ILC2s

enhanced the gene expression of mannose receptor C-type 1 (*MRC1*; encoding CD206, a well-known marker for M2 macrophage) in terms of both mRNA level (Fig. 6A) and protein level (Fig. 6B and 6C) compared with matched PD-1^{low} culture supernatant. The expression of M1 macrophage related genes (*TNF*, *IL6*, and *CCL5*) and M2 macrophage related genes (*TGFB1*, *CCL18*, and *ARG1*) (22) was also assessed. As expected, the expression of *TNF*, *IL6*, and *CCL5* in CD14⁺ cells treated with PD-1^{high} ILC2s supernatant was obviously decreased compared with matched PD-1^{low} ILC2s supernatant treated CD14⁺ monocytes or M1-like macrophages (Supplementary Fig. 5A). On the contrary, the expressions of M2 macrophage related genes (*TGFB1*, *CCL18*, and *ARG1*) in CD14⁺ monocytes treated with PD-1^{high} ILC2s supernatant were evidently increased compared with matched PD-1^{low} ILC2s supernatant treated CD14⁺ monocytes or M1-like macrophages (Supplementary Fig. 5B). These results suggested that some soluble molecules in the PD-1^{high} ILC2s culture supernatant boosted the polarization of M2-like macrophages from CD14⁺ monocytes. To assess whether elevated levels of IL-4 and IL-13 contributed to this phenomenon, we applied IL-4 and/or IL-13 neutralizing antibodies prior to treatment with PD-1^{high} ILC2s supernatant. The gene expression of *MRC1* in PD-1^{high} ILC2s supernatant was partially inhibited by anti-IL-4 antibody or anti-IL-13 antibody alone, and was almost abolished by a combination of anti-IL-4 and anti-IL-13 antibodies (Fig. 6D). Consistent results of corresponding protein levels were confirmed via flow cytometry (Fig. 6E and 6F). Furthermore, the expression of M2 macrophage related genes (*TGFB1*, *CCL18*, and *ARG1*) in CD14⁺ cells treated with PD-1^{high} ILC2s

supernatant was partially downregulated by anti-IL-4 antibody or anti-IL-13 antibody alone, and further inhibited by a combination of anti-IL-4 and anti-IL-13 antibodies (Supplementary Fig. 5C). These results indicated that IL-4 and IL-13 played a role in the process by which PD-1^{high} ILC2s induce the polarization of M2-like macrophages from CD14⁺ monocytes. Thus, we demonstrated that PD-1^{high} ILC2s enhanced the polarization of M2-like macrophages from CD14⁺ monocytes through the upregulation of IL-4 and IL-13, in vitro.

Discussion

ILCs, except for canonical NK cells, were new groups of lymphoid cells that were identified two decades ago (19). Since then, many studies on ILCs have been conducted in the fields of infectious and allergic diseases and, on a smaller scale, in tumors. Despite constituting a considerable proportion of immune cells in infection and allergy, the proportions of ILCs in tumors are relatively low, making it more difficult to investigate their roles in tumors. To our best knowledge, no published study has focused on ILC2s in human NSCLC to date. Thus, the present study assessed the distribution and functional features of ILC2s, as well as PD-1 expression and function on ILC2s in NSCLC patients.

We found no difference in the proportion of total ILCs in CD45⁺ cells between HDs and NSCLC patients; however, the proportions of ILC2s in bulk ILCs obtained from PBMCs and tumor tissues of NSCLC patients were significantly higher than those obtained from HD PBMCs. Similarly, Salimi et al. reported that ILC2s were enriched in human breast cancer tissues compared with tumor-adjacent tissues (29).

Moreover, we found that ILC2s in NSCLC patients expressed high levels of IL-4 and IL-13, which are classical type 2 cytokines, and might execute immunosuppressive function in human NSCLC. Similarly, a previous study reported that ILC2s contributed to melanoma progression by inhibiting NK cell activation and cytotoxicity in a mouse model, thereby functioning as an immunosuppressive factor (13). Another study showed that ILC2s facilitated tumor recurrence via the accumulation of MDSC

418 by upregulating IL-13 among patients with bladder cancer (14).

419 In a murine model of metastatic lung tumor (A9), a deficiency of ILC2s significantly
420 boosted tumor growth and metastasis, indicating that ILC2s might function as an
421 anti-tumor factor in murine lung cancer (30). However, the approach to deleting
422 ILC2s using $ROR\alpha^{-/-}$ mice in this study could unavoidably impair the development
423 and function of some other cells, which probably biased the research outcome.
424 Together, our findings indicated that ILC2s were enriched in human NSCLC and
425 might function as immunosuppressive cells via the upregulation of the type 2
426 cytokines IL-4 and IL-13.

427 In the area of adaptive immunity, PD-1 predominantly causes T cell function
428 inhibition and exhaustion (31,32). The downregulation of PD-1 may restore the
429 anti-tumor function of CD8⁺ T cells (33). Targeting the glycosylation of PD-1
430 enhances the cytotoxicity of chimeric antigen receptor T cells in tumor milieu (34).
431 Regarding PD-1 on ILC2s, Yong et al. reported that PD-1 was upregulated on ILC2
432 progenitor cells and mature ILC2s in lungs after influenza infection and that blocking
433 PD-1 on PD-1^{high} ILC2s using anti-PD-1 antibody dramatically reduced cytokine
434 (such as IL-13) production in the context of infection (23), indicating that PD-1 plays
435 an indispensable role in ILC2 development and function. In addition, a previous study
436 reported that PD-1 was exclusively expressed by ILC2s compared with ILC1s or
437 ILC3s in mice (26). With respect to tumor settings, Moral et al. reported that PD-1
438 was highly expressed on tumor-infiltrating ILC2s in human and mouse pancreatic

ductal adenocarcinoma (PDAC) (35). Similarly, we found that PD-1 was highly expressed in ILC2s compared with matched ILC1s or ILC3s in NSCLC patients. To explore the role of PD-1 upregulation in ILC2s, we sorted PD-1^{high} ILC2s and PD-1^{low} ILC2s from NSCLC tumor tissues by FACS and performed qPCR. Firstly, we confirmed that *PDCDI* expression was dramatically higher in PD-1^{high} ILC2s than PD-1^{low} ILC2s. Next, we assessed the expression of genes related to ILC2 phenotype, function, and immune checkpoint molecules. We found that *CRTH2* and *ST2* expression was more upregulated in PD-1^{high} ILC2s than in PD-1^{low} ILC2s. Since CRTH2 (the receptor for PGD2) and ST2 (the receptor of IL-33) are important functional cytomembrane proteins on ILC2s (36,37), their upregulation in PD-1^{high} ILC2s implies that PD-1 may enhance the function of ILC2s by boosting the PGD2-CRTH2 and IL-33-ST signaling pathways. We found no difference in the gene expression of the immune checkpoint receptors *CTLA4*, *HAVCR2*, and *LAG3*. Nevertheless, PD-1^{high} ILC2s showed an upregulation of *TIGIT*, which inhibited Th1 cytokine secretion in Treg cells (38) and enhanced IL-4 expression in follicular helper T cells (39), indicating that downregulation of TIGIT might contribute to the upregulation of IL-4 in PD-1^{high} ILC2s. Lastly, we found that IL-4 and IL-13 were highly expressed in PD-1^{high} ILC2s in terms of both mRNA and protein levels, indicating that PD-1^{high} ILC2s may enhance the type 2 immune response by upregulating IL-4 and IL-13 and act as immunosuppressive cells in human NSCLC. However, it was reported that PD-1 is a negative regulator in KLRG1⁺ILC2s cells in a murine model of worm infection and negatively regulates the function of ILC2s from

PBMCs of human HDs in vitro (26). The reasons for these contradictory findings may include: (i) the distinctive circumstances surrounding the immune response to worm infestation and tumor; (ii) our data were derived from NSCLC patients and represented real tumor data other than those ILC2s induced in HDs in vitro; and (iii) we did not compare the functional of ILC2s according to the different levels of KLRG1 due to the rarity of ILC2s. Another study showed that PD-1 inhibited the function of ILC2s and that anti-PD-1 therapy could expand ILC2s and augment anti-tumor immunity (35). However, the present study showed that high expression of PD-1 boosted the function of ILC2, such as enhancing IL4 and IL13 expression, in NSCLC patients. The following are possible reasons for the contradiction: (i) different cancers have distinctive tumor microenvironments; (ii) our study was performed ex vivo which may not reflect the effect of multiple factors in vivo, including the ligation of PD-1 and PD-1 ligands and IL-33 activation by ILC2s; and (iii) we speculated that PD-1 upregulation represented activation in the early stage of ILC2s but functioned as an inhibitory factor in later stages, similar to cytotoxic T cells (32). Indeed, a previous study demonstrated that PD-1 expression on ILC2s was upregulated after ILC2 activation by IL-33 in obese mice (40). Thus, in the present study, we found that PD-1 upregulation might be due to ILC2 activation and represented a high-functioning stage in NSCLC ILC2s.

In this study, we found that the phosphorylation levels of AKT and S6 were increased in PD-1^{high} ILC2s, indicating that the PD-1 downstream signaling pathway could be activated in ILC2s obtained from NSCLC patients. However, phosphorylated STAT5,

which was reported to be involved in the regulation of cytokine secretion in PD-1 expressing ILC2s in the context of *Nippostrongylus brasiliensis* infection (26), showed no difference in PD-1^{high} ILC2s and PD-1^{low} ILC2s among NSCLC patients. Thus, further studies are needed to elucidate the mechanism by which PD-1 regulates the downstream signaling in ILC2s obtained from NSCLC patients.

In the present study, we found that PD-1^{high} ILC2 culture supernatant enhanced the expression of *MRC1* (encoding CD206, a typical marker of M2 macrophages) and other M2 macrophage related genes (*TGFBI*, *CCL18*, and *ARG1*), and diminished the expression of M1 macrophage related genes (*TNF*, *IL6*, and *CCL5*). Moreover, anti-IL-4 antibody and/or anti-IL-13 antibody could weaken the upregulation of M2 macrophage related genes induced by PD-1^{high} ILC2 culture supernatant. These findings demonstrated that the upregulation of PD-1 on ILC2s could enhance M2-like macrophage polarization from CD14⁺ monocytes by facilitating the production of IL-4 and IL-13. Our findings were in line with some previous reports that IL-4 and IL-13 could mediate M2 macrophage polarization in vitro (27,28).

Dupilumab, a monoclonal antibody against human IL-4 receptor α , inhibits both IL-4 and IL-13 signaling and has been confirmed to be effective in phase 3 clinical trials of asthma and atopic dermatitis (41,42). IL-4 and IL-13 were upregulated in ILC2s cells, particularly in PD-1^{high} ILC2s in NSCLC patients, and boosted M2-like macrophage polarization, warranting clinical trials of Dupilumab in NSCLC patients in the future.

The present study had some limitations. Firstly, due to the rarity of ILC2s in clinical

samples, we could not assess the expression of related proteins using available methods, such as western blot assay. Secondly, we only conducted an exploratory study on PD-1 downstream signaling via flow cytometry, and further research is needed to confirm the PD-1 signaling pathway in ILC2s, particularly the molecules involved in the regulation of IL-4 and IL-13 in ILC2s. Thirdly, since there were not enough ILC2s for adaptive transfer assay, we did not ascertain the immunosuppressive function of ILC2s in vivo. Thus, well-designed studies are needed to confirm the detailed function of ILC2s in human NSCLC.

Conclusions

In summary, for the first time, we report that ILC2s are enriched in NSCLC patients. PD-1 is upregulated on ILC2s in NSCLC patients, and PD-1^{high} ILC2s yield a more immunosuppressive function by upregulating IL-4 and IL-13 expression and enhance M2-like macrophage polarization. PD-1 is a positive regulator of immunosuppressive ILC2s in human NSCLC.

Abbreviations

ILC1s: group 1 innate lymphoid cells; ILC2s: group 2 innate lymphoid cells; ILC3s: group 3 innate lymphoid cells; HD: health donor; NSCLC: non-small cell lung cancer; FACS: fluorescence activated cell sorting; PD-1: programmed cell death protein 1; CTLA4: cytotoxic T lymphocyte-associated antigen 4; TIM3: T-cell immunoglobulin domain and mucin domain 3; LAG3: Lymphocyte activation gene-3; TIGIT: T-cell immunoglobulin and ITIM domains; PBMCs: peripheral blood mononuclear cells; MDSCs: myeloid-derived suppressor cells; qRT-PCR: quantitative Real-Time Polymerase Chain Reaction; MACS: Magnetic-Activated Cell Sorting; rhM-CSF: Recombinant Human macrophage colony-stimulating factor.

Ethics approval and consent to participate

All experimental procedures were approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University, Henan, China.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. U1804281 and 81771781) and the National Key Research and Development Project of China (grant no. 2018YFC1313400).

Authors' contributions

Conception and design: Y. Zhang, C. Liu, C. Shen; **Development of methodology:** C. Liu, C. Shen, Z. Zhang; **Acquisition of data (acquired and managed patients, provided facilities, etc.):** Y. Zhang, C. Liu, C. Shen, J. Shao, L. Wang, Y. Tian; **Analysis and interpretation of data (e.g. statistical analysis, biostatistics, computational analysis):** C. Liu, C. Shen, W. Yu, G. Qin, Y. Ping, S. Liu; **Writing, review, and/or revision of the manuscript:** Y. Zhang, C. Liu, C. Shen; **Administrative, technical, or material support (i.e. reporting or organizing data,**

constructing databases): C. Liu, C. Shen, J. Shao, W. Yu; Study supervision: Y.

Zhang, Z. Zhang

Acknowledgments

We thank the staff and students of the Biotherapy Center at the First Affiliated Hospital of Zhengzhou University for their invaluable help in this study.

References

1. Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. *Immunity* 2014;41(3):354-65.
2. Kansler ER, Li MO. Innate lymphocytes-lineage, localization and timing of differentiation. *Cell Mol Immunol* 2019;16(7):627-33.
3. Seillet C, Jacquelot N. Sensing of physiological regulators by innate lymphoid cells. *Cell Mol Immunol* 2019;16(5):442-51.
4. Fang D, Zhu J. Dynamic balance between master transcription factors determines the fates and functions of CD4 T cell and innate lymphoid cell subsets. *J Exp Med* 2017;214(7):1861-76.
5. Farrar JD, Ouyang W, Lohning M, Assenmacher M, Radbruch A, Kanagawa O, et al. An instructive component in T helper cell type 2 (Th2) development mediated by GATA-3. *J Exp Med* 2001;193(5):643-50.
6. Hoyler T, Klose CS, Souabni A, Turqueti-Neves A, Pfeifer D, Rawlins EL, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. *Immunity* 2012;37(4):634-48.
7. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine* 2015;75(1):14-24.
8. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Cell* 2010;140(6):883-99.
9. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu Rev Immunol* 2012;30:677-706.
10. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. *Nat Immunol* 2013;14(6):536-42.
11. Kim BS, Artis D. Group 2 innate lymphoid cells in health and disease. *Cold Spring Harb Perspect Biol* 2015;7(5).
12. Inclan-Rico JM, Siracusa MC. First Responders: Innate Immunity to Helminths. *Trends Parasitol* 2018;34(10):861-80.
13. Long A, Dominguez D, Qin L, Chen S, Fan J, Zhang M, et al. Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor Suppression. *J Immunol* 2018;201(11):3456-64.

- 602 14. Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, et al. ILC2-modulated T
603 cell-to-MDSC balance is associated with bladder cancer recurrence. *Journal of Clinical*
604 *Investigation* 2017;127(8):2916-29.
- 605 15. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN,
606 et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating
607 intratumoral accumulation of immunosuppressive and innate lymphoid cells. *Int J Cancer*
608 2014;134(7):1669-82.
- 609 16. Trabanelli S, Chevalier MF, Derre L, Jandus C. The pro- and anti-tumor role of ILC2s. *Semin*
610 *Immunol* 2019:101276.
- 611 17. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
612 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
613 countries. *CA Cancer J Clin* 2018;68(6):394-424.
- 614 18. Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R, et al. NCR(+)ILC3
615 concentrate in human lung cancer and associate with intratumoral lymphoid structures. *Nat*
616 *Commun* 2015;6:8280.
- 617 19. Artis D, Spits H. The biology of innate lymphoid cells. *Nature* 2015;517(7534):293-301.
- 618 20. Munneke JM, Bjorklund AT, Mjosberg JM, Garming-Legert K, Bernink JH, Blom B, et al.
619 Activated innate lymphoid cells are associated with a reduced susceptibility to
620 graft-versus-host disease. *Blood* 2014;124(5):812-21.
- 621 21. Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, et al. Impaired T cell function in malignant
622 pleural effusion is caused by TGF-beta derived predominantly from macrophages. *Int J Cancer*
623 2016;139(10):2261-9.
- 624 22. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human
625 monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene
626 expression. *J Immunol* 2006;177(10):7303-11.
- 627 23. Yu Y, Tsang JC, Wang C, Clare S, Wang J, Chen X, et al. Single-cell RNA-seq identifies a
628 PD-1(hi) ILC progenitor and defines its development pathway. *Nature* 2016;539(7627):102-6.
- 629 24. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt
630 and Ras pathways regulate molecular components of the cell cycle and inhibit T cell
631 proliferation. *Sci Signal* 2012;5(230):ra46.
- 632 25. Kleffel S, Posch C, Barthel Steven R, Mueller H, Schlapbach C, Guenova E, et al. Melanoma
633 Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. *Cell* 2015;162(6):1242-56.
- 634 26. Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo TC, Sun MA, et al. PD-1 regulates
635 KLRG1(+) group 2 innate lymphoid cells. *J Exp Med* 2017;214(6):1663-78.
- 636 27. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively
637 activated macrophages: roles in homeostasis and disease. *Annu Rev Immunol*
638 2013;31:317-43.
- 639 28. Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, et al. Blocking Interleukin
640 (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of
641 Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory
642 Breast Cancer. *Int J Radiat Oncol Biol Phys* 2018;100(4):1034-43.
- 643 29. Salimi M, Wang R, Yao X, Li X, Wang X, Hu Y, et al. Activated innate lymphoid cell
644 populations accumulate in human tumour tissues. *BMC Cancer* 2018;18(1):341.
- 645 30. Saranchova I, Han J, Zaman R, Arora H, Huang H, Fenninger F, et al. Type 2 Innate

Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis. *Sci Rep* 2018;8(1):2924.

31. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol* 2015;15(8):486-99.
32. Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell Dysfunction and Exhaustion in Cancer. *Front Cell Dev Biol* 2020;8:17.
33. Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al. Metformin Enhances the Antitumor Activity of CD8(+) T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway. *J Immunol* 2020;204(9):2575-88.
34. Shi X, Zhang D, Li F, Zhang Z, Wang S, Xuan Y, et al. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity. *J Hematol Oncol* 2019;12(1):127.
35. Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. *Nature* 2020;579(7797):130-5.
36. Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salome B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. *Nat Commun* 2017;8(1):593.
37. Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. *J Allergy Clin Immunol* 2013;132(4):933-41.
38. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity* 2014;40(4):569-81.
39. Godefroy E, Zhong H, Pham P, Friedman D, Yazdanbakhsh K. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. *Haematologica* 2015;100(11):1415-25.
40. Oldenhove G, Boucquoy E, Taquin A, Acolty V, Bonetti L, Ryffel B, et al. PD-1 Is Involved in the Dysregulation of Type 2 Innate Lymphoid Cells in a Murine Model of Obesity. *Cell Rep* 2018;25(8):2053-60 e4.
41. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β 2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *The Lancet* 2016;388(10039):31-44.
42. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med* 2016;375(24):2335-48.

Figure legends

Figure 1. Identification and distribution of group 2 innate lymphoid cells in healthy donors and NSCLC patients. **(A)** The representative gating strategy of human ILCs ($CD45^{+}Lin^{-}(CD3, CD14, CD16, CD19, CD20, CD56)^{-}CD127^{+}$). ILC1s: $CD45^{+}Lin^{-}CD127^{+}CRTH2^{+}CD117^{-}$; ILC2s: $CD45^{+}Lin^{-}CD127^{+}CRTH2^{+}$; ILC3s: $CD45^{+}Lin^{-}CD127^{+}CRTH2^{+}CD117^{+}$. **(B)** The proportions of total ILCs among $CD45^{+}$ cells from HD-PB (PBMCs from healthy donors, n=20), LU-PB (PBMCs from NSCLC patients, n=20), and LU-CA (tumor single cell suspension from NSCLC patients, n=20). **(C)** The representative results of ILC subset distribution in HD-PB, LU-PB, and LU-CA samples assessed via flow cytometry. **(D)** The proportions of ILC2s among total ILCs in HD-PB, LU-PB, and LU-CA (for each group, n=20). **(E)** The proportions of ILC2s among total ILCs of LU-CA at different stages (for each group, n=20). NS, not significant; ****, $P<0.0001$. In Figures **B** and **D**, P values were calculated by one-way ANOVA and post hoc comparisons were performed via Tukey's test. In Figure **E**, P values were obtained in a non-paired two-tailed student's t -test.

Figure 2. mRNA and protein expression of key functional molecules of ILC2s. **(A–C)** ILC2s were marked as $CD45^{+}Lin^{-}CD127^{+}CRTH2^{+}$ and sorted via FACS. **(A)** A heatmap showing representative results of mRNA expression of the key functional molecules of ILC2s obtained from HD-PB, LU-PB, and LU-CA samples. **(B, C)** The relative mRNA expressions of *IL4* **(B)** and *IL13* **(C)** in ILC2s from HD-PB, LU-PB, and LU-CA samples (for each group, n=18). **(D–G)** Protein expression of IL-4 **(D, E)** and IL-13 **(F, G)** in ILC2s from HD-PB, LU-PB, and LU-CA samples assessed via flow cytometry (for each group, n=20). HD-PB: PBMCs from healthy donors, LU-PB: PBMCs from NSCLC patients, and LU-CA: tumor single cell suspension from NSCLC patients. NS, not significant; *, $P<0.05$; ***, $P<0.001$; ****, $P<0.0001$. P values were calculated by one-way ANOVA and post hoc comparisons were performed via Tukey's test.

Figure 3. mRNA and protein expression of immune checkpoint molecules of ILC2s. (A-C) ILC2s were marked as CD45⁺Lin⁻CD127⁺CRTH2⁺ and sorted by FACS. (A) A heatmap showing representative results of relative mRNA expression of *PDCDI*, *CTLA4*, *HAVCR2* (encoding TIM3), *LAG3*, and *TIGIT* on ILC2s in HD-PB, LU-PB, and LU-CA samples. (B) The relative mRNA expression of *PDCDI* on ILC2s from HD-PB, LU-PB, and LU-CA samples (for each group, n=18). (C) The protein expression of PD-1 on total ILCs obtained from HD-PB, LU-PB, and LU-CA samples (for each group, n=18). (D-G) The representative results and statistical results of PD-1 protein expression on ILCs subsets in LU-PB (D, E) and LU-CA (F, G) assessed by flow cytometry (for each group, n=30). NS, not significant; *, $P<0.05$; **, $P<0.01$; ****, $P<0.0001$. P values were calculated by one-way ANOVA and post hoc comparisons were performed via Tukey's test.

Figure 4. PD-1^{high} ILC2s expressed higher levels of IL-4 and IL-13. PD-1^{high} ILC2s and PD-1^{low} ILC2s were marked as CD45⁺Lin⁻CD127⁺CRTH2⁺PD-1^{high} and CD45⁺Lin⁻CD127⁺CRTH2⁺PD-1^{low}, respectively, and sorted by FACS. (A-B) The gene expressions of *PDCDI* (encoding PD-1) (A), *IL4*, and *IL13* (B) were upregulated in the PD-1^{high} group compared with the matched PD-1^{low} group (n=26). (C-F) The representative results and statistical results of IL-4 (C-D) and IL-13 (E-F) protein expression according to the different PD-1 levels assessed by flow cytometry (for each group, n=26). Each dot represents one sample. ***, $P<0.001$; ****, $P<0.0001$. P values were calculated using a paired two-tailed student's t -test.

Figure 5. Upregulation of the PD-1 activated AKT-S6 signaling pathway in ILC2s obtained from NSCLC tumor tissues. (A-B) Phosphorylated AKT level was increased in PD-1^{high} ILC2s compared with matched PD-1^{low} ILC2s (n=6, $P=0.0029$). (C-D) Phosphorylated S6 level was increased in PD-1^{high} ILC2s compared with matched PD-1^{low} ILC2s (n=6, $P=0.0055$). (E-F) There was no difference in the levels of phosphorylated STAT5 between PD-1^{high} ILC2s and PD-1^{low} ILC2s (n=6). NS, not significant; **, $P<0.01$. P values were calculated using a paired two-tailed student's

t-test.

Figure 6. PD-1^{high} ILC2s enhanced the polarization of M2-like macrophages by upregulating IL-4 and IL-13 in vitro. (A–C) Sorted CD14⁺ monocytes from HD PBMCs were treated with recombinant human M-CSF for seven days, and then mixed with LPS and IFN γ (for M1-like macrophages) or IL-4 (for M2-like macrophages) or PD-1^{high} ILC2s culture supernatant or PD-1^{low} ILC2s culture supernatant for an additional 18 hours. The CD14⁺ cells were harvested for qPCR and flow cytometry. (A) PD-1^{high} ILC2 culture supernatant enhanced *MRC1* (encoding CD206, a well-known M2 macrophage marker) mRNA expression compared with PD-1^{low} ILC2 culture supernatant treated with CD14⁺ cells. (B–C) The CD206 protein expression was assessed via flow cytometry, the representative results (B) and statistical results (C) (n=6) of which are shown. (D–F) CD14⁺ monocytes sorted from HD PBMCs were treated with recombinant human M-CSF for seven days and divided into four groups to which the following were added: the solute, anti-IL-4 antibody, anti-IL-13 antibody, and a combination of anti-IL-4 and anti-IL-13 antibodies, respectively. Two hours later, LPS and PD-1^{high} ILC2 supernatant were added to all groups and cultured for another 18 hours. (D) Anti-IL-4 and/or anti-IL-13 antibodies decreased the mRNA expression of *MRC1*. (E–F) The levels of CD206 were diminished after IL-4 and/or IL-13 blockade testing by flow cytometry, the representative results (E) and statistical results (F) (n=5) of which are shown. NS, not significant; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$. P values were calculated by one-way ANOVA and post hoc comparisons were performed via Tukey's test.

Figure 1

785 Figure 2

786

787

788

789

790

791

792

793

794

795

796

797 Figure 3

810

811

812

813

814

Figure 5

834 Figure 6

835

836

837

838

839

840

841

842

843

844

845

846

Supplementary Figure Legends

Supplementary Figure S1. Proportions of three subsets in total ILCs from health donors and NSCLC patients. **(A)** The distribution of three subsets of ILCs from HD-PB (PBMCs from health donors), LU-PB (PBMCs from NSCLC patients) and LU-CA (tumor single cell suspension from NSCLC patients) via flow cytometry. **(B)** The proportions of ILC1s in HD-PB, LU-PB and LU-CA samples (for each group, $n=20$). **(C)** The proportions of ILC3s in HD-PB, LU-PB and LU-CA (for each group, $n=20$). **(D)** The proportions of different ILC subsets in total ILCs from tumor tissue of NSCLC patients at different stages (for each group, $n=20$). **(E, F)** The proportions of ILC1s **(E)** and ILC3s **(F)** in total ILCs of LU-CA at different stages (for each group, $n=20$). NS, not significant, **, $P<0.01$, ***, $P<0.001$, ****, $P<0.0001$. In Figure **B** and **C**, P values were calculated by one-way ANOVA, post hoc comparisons, Tukey's test. In Figure **E** and **F**, P values were calculated by non-paired two-tailed Student t-test.

Supplementary Figure S2. Gene expression of surface markers and functional molecules of ILC2s from HDs and NSCLC patients. The mRNA expression of surface marker genes **(A)** and functional molecules genes **(B)** of ILC2s sorted from HD-PB, LU-PB and LU-CA samples was tested by qPCR (for each group, $n=18$). ILC2s were marked as $CD45^{+}Lin^{-}CD127^{+}CRTH2^{+}$. HD-PB: PBMCs from health donors, LU-PB: PBMCs from NSCLC patients, and LU-CA: tumor single cell suspension from NSCLC patients. NS, not significant, *, $P<0.05$, **, $P<0.01$, ***, $P<0.001$, ****, $P<0.0001$. P values were calculated by one-way ANOVA, post hoc comparisons, Tukey's test.

Supplementary Figure S3. Gene expression of immune checkpoint molecules of ILC2s from health donors and NSCLC patients. ILC2s were sorted by FACS. The mRNA expression of other immune checkpoint genes in ILC2s from HD-PB, LU-PB and LU-CA samples was tested by qPCR (for each group, $n=18$). NS, no significant, *,

P<0.05. *P* values were calculated by one-way ANOVA, post hoc comparisons, Tukey's test.

Supplementary Figure S4. Gene expression of surface markers, immune checkpoint molecules and functional molecules of PD-1^{high} and PD-1^{low} ILC2s from tumor tissue of NSCLC patients. PD-1^{high} ILC2s and PD-1^{low} ILC2s were marked and sorted as described in Figure 4. (A) The mRNA expression of surface marker genes of ILC2s sorted from HD-PB, LU-PB and LU-CA samples (n=26). (B) The mRNA expression of other immune checkpoint genes in ILC2s from HD-PB, LU-PB and LU-CA samples. (C) The mRNA expression of other functional genes in ILC2s from HD-PB, LU-PB and LU-CA samples. NS, not significant, *, *P*<0.05. *P* values were calculated by paired two-tailed Student t-test.

Supplementary Figure S5. PD-1^{high} ILC2s boosted M2 related genes expression and downregulated M1 related genes through secreting IL-4 and IL-13. (A-B) PD-1^{high} ILC2s culture supernatant downregulated M1 related genes (*TNF*, *IL6* and *CCL5*) expression (A) and upregulated M2 related genes (*TGFB1*, *CCL18* and *ARG1*) expressions (B). (C) Anti-IL-4 antibody and/or anti-IL-13 antibody weakened the upregulation of M2 related genes expression in CD14⁺ cells treated by PD-1^{high} ILC2s culture supernatant. NS, not significant, *, *P*<0.05, **, *P*<0.01, ***, *P*<0.001, ****, *P*<0.0001. *P* values were calculated by one-way ANOVA, post hoc comparisons, Tukey's test.

Supplementary Figure 3

966

967

968

969

970

971

972

Supplementary Table S1. Clinical pathological characteristics of patients with NSCLC

Patient characteristics		NSCLC patients (n=70) n (%)
Gender	Male	38 (54.3 %)
	Female	32 (45.7 %)
Age (years)	< 60	31 (44.3 %)
	≥ 60	39 (55.7 %)
Smoking history	Yes	33 (47.1 %)
	No	37 (52.9 %)
Histological type	Squamous carcinoma	33 (47.1 %)
	Adenocarcinoma	37 (52.9 %)
Histological grade	I	11 (15.7 %)
	II	23 (32.9 %)
	III	36 (51.4 %)
TNM stage	I-II	30 (42.9 %)
	III-IV	40 (57.1 %)
Lymph node metastasis	Yes	38 (54.3 %)
	No	32 (45.7 %)

989 **Supplementary Table S2. Primers for quantitative real-time PCR**

Gene			
Name	Primer Forward	Primer Reverse	PCR product
<i>AREG</i>	CCAAAACAAGACGGAAAGTGA	TGTTACTGCTTCCAGGTGCTC	175bp
<i>ARG1</i>	TGGACAGACTAGGAATTGGCA	CCAGTCCGTCAACATCAAAACT	102bp
<i>CCL5</i>	CTCCCCATATTCCTCGGACA	GTTGATGTACTCCCGAACCC	190bp
<i>CCL18</i>	TACCTCCTGGCAGATTCCAC	CCCCTTCTTATTGGGGTCA	131bp
<i>CRTN2</i>	CTGGGCAAGTGCCTCCTAAG	CAACGAGTTGTCCAATGCGG	93bp
<i>CTLA4</i>	CATGATGGGGAATGAGTTGACC	TCAGTCCTTGGATAGTGAGGTTC	92bp
<i>GADPH</i>	GCACCGTCAAGGCTGAGAAC	TGGTGAAGACGCCAGTGGA	138bp
<i>HAVCR2</i>	CTGCTGCTACTACTTACAAGGTC	GCAGGGCAGATAGGCATTCT	75bp
<i>IL13</i>	GGTCAACATCACCCAGAACC	GATTCCAGGGCTGCACAGTA	99bp
<i>IL4</i>	TCCGATTCCTGAAACGGCTC	TGGTTGGCTTCCTTCACAGG	79bp
<i>IL5</i>	CGAACTCTGCTGATAGCCAA	CAGTACCCCTTGACAGTT	130bp
<i>IL6</i>	GAACCTTCCAAAGATGGC	CAAATCTGTTCTGGAGGT	131bp
<i>IL7R</i>	CTCCAACCGGCAGCAATGTAT	AGATGACCAACAGAGCGACAG	193bp
<i>IL9</i>	CTTCTGGCCATGGTCCTTAC	CATGGTCTGGTGCAGTTGTC	200bp
<i>KIT</i>	ACTTGAGGTTTATTCCTGACCCC	GCAGACAGAGCCGATGGTAG	78bp
<i>LAG3</i>	GCCTCCGACTGGGTCATTTT	CTTTCCGCTAAGTGGTGATGG	131bp
<i>MRC1</i>	GGGTTGCTATCACTCTCTATGC	TTTCTTGTCTGTTGCCGTAGTT	126bp
<i>PDCD1</i>	CCAAGGCGCAGATCAAAGAGA	AGGACCCAGACTAGCAGCA	175bp
<i>ST2</i>	ATGGGGTTTTGGATCTTAGCAAT	CACGGTGTAAGTAGGTTTTCTT	138bp
<i>TGFB1</i>	GGCCAGATCCTGTCCAAGC	GTGGGTTTCCACCATTAGCAC	201bp
<i>TIGIT</i>	TCTGCATCTATCACACCTACCC	CCACCACGATGACTGCTGT	162bp
<i>TNF</i>	GAGGCCAAGCCCTGGTATG	CGGGCCGATTGATCTCAGC	91bp

990

991

Figures

CD127+CRTH2+CD117+. (B) The proportions of total ILCs among CD45+ cells from HD PB (PBMCs from healthy donors, n=20), LU PB (PBMCs from NSCLC patients, n=20), and LU CA (tumor single cell suspension from NSCLC patients, n=20). (C) The representative results of ILC subset distribution in HD PB, LU PB, and LU CA samples assessed via flow cytometry. (D) The proportions of ILC2s among total ILCs in HD PB, LU PB, and LU CA (for each group, n=20). (E) The proportions of ILC2s among total ILCs of LU CA at different stages (for each group, n=20). NS, not significant; ****, $P < 0.0001$. In Figures B and D, P values were calculated by one way ANOVA and post hoc comparisons were performed via Tukey's test. In Figure E, P values were obtained in a non paired two tailed student's t test.

Figure 2

mRNA and protein expression of key functional molecules of ILC2s. (A C) ILC2s were marked as CD45⁺Lin⁻CD127⁺CRTH2⁺ and sorted via FACS. (A) A heatmap showing representative results of mRNA expression of the key functional molecules of ILC2s obtained from HD PB, LU PB, and LU CA samples. (B, C) The relative mRNA expressions of IL4 (B) and IL13 (C) in ILC2s from HD PB, LU PB, and LU CA samples (for each group, n=18). (D G) Protein expression of IL 4 (D, E) and IL 13 (F, G) in ILC2s from HD

PB, LU PB, and LU CA samples assessed via flow cytometry (for each group, n=20). HD PB: PBMCs from healthy donors, LU PB: PBMCs from NSCLC patients, and LU CA: tumor single cell suspension from NSCLC patients. NS, not significant; *, P<0.05; ***, P<0.001; ****, P<0.0001. P values were calculated by one way ANOVA and post hoc comparisons were performed via Tukey's test.

Figure 3

mRNA and protein expression of immune checkpoint molecules of ILC2s. (A C) ILC2s were marked as CD45⁺Lin⁺ CD127⁺CRTH2⁺ and sorted by FACS. (A) A heatmap showing representative results of relative

mRNA expression of PDCD1, CTLA4, HAVCR2 (encoding TIM3), LAG3, and TIGIT on ILC2s in HD PB, LU PB, and LU CA samples. (B) The relative mRNA expression of PDCD1 on ILC2s from HD PB, LU PB, and LU CA samples (for each group, n=18). (C) The protein expression of PD 1 on total ILCs obtained from HD PB, LU PB, and LU CA samples (for each group, n=18). (D G) The representative results and statistical results of PD 1 protein expression on ILCs subsets in LU PB (D, E) and LU CA (F, G) assessed by flow cytometry (for each group, n=30). NS, not significant; *, P<0.05; **, P<0.01; ****, P<0.0001. P values were calculated by one way ANOVA and post hoc 723 comparisons were performed via Tukey's test.

Figure 4

PD 1^{high} ILC2s expressed higher levels of IL 4 and IL 13. PD 1^{high} ILC2s and PD 1^{low} ILC2s were marked as CD45⁺Lin⁺CD127⁺CRTH2⁺PD 1^{high} and CD45⁺Lin⁺CD127⁺CRTH2⁺PD 1^{low}, respectively, and sorted by FACS. (A B) The gene expressions of PDCD1 (encoding PD 1) (A), IL4, and IL13 (B) were upregulated in the PD 1^{high} group compared with the matched PD 1^{low} group (n=26). (C F) The representative results and statistical results of IL 4 (C D) and IL 13 (E F) protein expression according to the different PD 1 levels assessed by flow cytometry (for each group, n=26). Each dot represents one sample. ***, P<0.001; ****, P<0.0001. P values were calculated using a paired two tailed student's t test.

Figure 5

Upregulation of the PD 1 activated AKT S6 signaling pathway in ILC2s obtained from NSCLC tumor tissues. (A B) Phosphorylated AKT level was increased in PD 1^{high} ILC2s compared with matched PD 1^{low} ILC2s (n=6, P=0.0029). (C D) Phosphorylated S6 level was increased in PD 1^{high} ILC2s compared with matched PD 1^{low} ILC2s (n=6, P=0.0055). (E F) There was no difference in the levels of phosphorylated STAT5 between PD 1^{high} ILC2s and PD 1^{low} ILC2s (n=6). NS, not significant; **, P<0.01. P values were calculated using a paired two tailed student's t-test.

Figure 6

PD 1^{high} ILC2s enhanced the polarization of M2 like macrophages by upregulating IL 4 and IL 13 in vitro. (A C) Sorted CD14⁺ monocytes from HD PBMCs were treated with recombinant human M-CSF for seven days, and then mixed with LPS and IFN γ (for M1 like macrophages) or IL 4 (for M2 like macrophages) or PD 1^{high} ILC2s culture supernatant or PD 1^{low} ILC2s culture supernatant for an additional 18 hours. The CD14⁺ cells were harvested for qPCR and flow cytometry. (A) PD 1^{high} ILC2 culture supernatant enhanced MRC1 (encoding CD206, a well known M2 macrophage marker) mRNA expression compared

with PD 1low ILC2 culture supernatant treated with CD14+ cells. (B C) The CD206 protein expression was assessed via flow cytometry, the representative results (B) and statistical results (C) (n=6) of which are shown. (D F) CD14+ monocytes sorted from HD PBMCs were treated with recombinant human M-CSF for seven days and divided into four groups to which the following were added: the solute, anti IL 4 antibody, anti IL 13 antibodies, respectively. Two hours later, LPS and PD 1high ILC2 supernatant were added to all groups and cultured for another 18 hours. (D) Anti IL 4 and/or anti IL 13 antibodies decreased the mRNA expression of MRC1. (E F) The levels of CD206 were diminished after IL 4 and/or IL 13 blockade testing by flow cytometry, the representative results (E) and statistical results (F) (n=5) of which are shown. NS, not significant; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$. P values were calculated by one way ANOVA and post hoc comparisons were performed via Tukey's test.